Daxor Corporation (DXR)
USD 8.2
(-0.97%)
USD 8.2
(-0.97%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | -177.07 Thousand USD | -93.72% |
| 2022 | 5.25 Million USD | 10.58% |
| 2021 | 4.74 Million USD | 374.36% |
| 2020 | -1.73 Million USD | -249.14% |
| 2019 | -495.69 Thousand USD | 54.82% |
| 2018 | -1.09 Million USD | 3.96% |
| 2017 | -1.14 Million USD | -177.85% |
| 2016 | 1.46 Million USD | 118.62% |
| 2015 | -7.88 Million USD | -74.86% |
| 2014 | -4.5 Million USD | 45.16% |
| 2013 | -8.21 Million USD | -206.06% |
| 2012 | -2.68 Million USD | 53.59% |
| 2011 | -5.78 Million USD | -169.3% |
| 2010 | 8.35 Million USD | 16.75% |
| 2009 | 7.15 Million USD | -63.66% |
| 2008 | 19.68 Million USD | 64.58% |
| 2007 | 11.95 Million USD | 1622.31% |
| 2006 | -785.53 Thousand USD | 41.2% |
| 2005 | -1.33 Million USD | -130.24% |
| 2004 | -580.26 Thousand USD | 44.84% |
| 2003 | -1.05 Million USD | -513.35% |
| 2002 | -171.5 Thousand USD | -146.46% |
| 2001 | 369.1 Thousand USD | -68.13% |
| 2000 | 1.15 Million USD | 1309.27% |
| 1999 | -95.77 Thousand USD | -110.64% |
| 1998 | 900 Thousand USD | 550.0% |
| 1997 | -200 Thousand USD | -133.33% |
| 1996 | 600 Thousand USD | -72.73% |
| 1995 | 2.2 Million USD | -24.14% |
| 1994 | 2.9 Million USD | -17.14% |
| 1993 | 3.5 Million USD | -30.0% |
| 1992 | 5 Million USD | 1350.0% |
| 1991 | -400 Thousand USD | -107.84% |
| 1990 | 5.1 Million USD | 410.0% |
| 1989 | 1 Million USD | -81.13% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q2 | -148.77 Thousand USD | 0.0% |
| 2024 Q1 | -148.77 Thousand USD | -104.85% |
| 2023 Q3 | -210.79 Thousand USD | 92.96% |
| 2023 Q1 | -183.22 Thousand USD | -102.6% |
| 2023 FY | 329.74 Thousand USD | -93.72% |
| 2023 Q4 | 3.06 Million USD | 1553.97% |
| 2023 Q2 | -2.99 Million USD | -1533.32% |
| 2022 Q4 | 7.03 Million USD | 2354.34% |
| 2022 Q3 | -312.1 Thousand USD | 82.78% |
| 2022 Q1 | -117.76 Thousand USD | -101.87% |
| 2022 FY | 5.25 Million USD | 10.58% |
| 2022 Q2 | -1.81 Million USD | -1439.11% |
| 2021 Q3 | -224.49 Thousand USD | 85.5% |
| 2021 Q2 | -1.54 Million USD | -944.34% |
| 2021 FY | 4.74 Million USD | 374.36% |
| 2021 Q4 | 6.29 Million USD | 2904.88% |
| 2021 Q1 | -148.29 Thousand USD | -108.05% |
| 2020 Q1 | -51.87 Thousand USD | 94.43% |
| 2020 Q2 | -3.54 Million USD | -6740.36% |
| 2020 FY | -1.73 Million USD | -249.14% |
| 2020 Q3 | -117.09 Thousand USD | 96.7% |
| 2020 Q4 | 1.84 Million USD | 1673.83% |
| 2019 Q3 | -5465.00 USD | -101.06% |
| 2019 FY | -495.69 Thousand USD | 54.82% |
| 2019 Q1 | 16.18 Thousand USD | -43.7% |
| 2019 Q2 | 517.36 Thousand USD | 3096.54% |
| 2019 Q4 | -931.61 Thousand USD | -16946.86% |
| 2018 Q1 | 57.85 Thousand USD | -44.43% |
| 2018 Q3 | 28.74 Thousand USD | -50.31% |
| 2018 Q4 | 28.74 Thousand USD | 0.0% |
| 2018 FY | -1.09 Million USD | 3.96% |
| 2018 Q2 | 57.85 Thousand USD | 0.0% |
| 2017 Q3 | 104.11 Thousand USD | -4.74% |
| 2017 Q4 | 104.11 Thousand USD | 0.0% |
| 2017 FY | -1.14 Million USD | -177.85% |
| 2017 Q1 | 109.29 Thousand USD | 53.05% |
| 2017 Q2 | 109.29 Thousand USD | 0.0% |
| 2016 Q2 | 42.96 Thousand USD | 0.0% |
| 2016 FY | 1.46 Million USD | 118.62% |
| 2016 Q4 | 71.41 Thousand USD | 0.0% |
| 2016 Q3 | 71.41 Thousand USD | 66.23% |
| 2016 Q1 | 42.96 Thousand USD | -60.35% |
| 2015 FY | -7.88 Million USD | -74.86% |
| 2015 Q3 | 108.34 Thousand USD | -52.19% |
| 2015 Q4 | 108.34 Thousand USD | 0.0% |
| 2015 Q2 | 226.6 Thousand USD | 0.0% |
| 2015 Q1 | 226.6 Thousand USD | -27.18% |
| 2014 Q2 | 296.1 Thousand USD | 0.0% |
| 2014 FY | -4.5 Million USD | 45.16% |
| 2014 Q1 | 296.1 Thousand USD | -32.25% |
| 2014 Q4 | 311.16 Thousand USD | 0.0% |
| 2014 Q3 | 311.16 Thousand USD | 5.09% |
| 2013 Q4 | 437.04 Thousand USD | 0.0% |
| 2013 Q1 | 403.85 Thousand USD | -23.0% |
| 2013 FY | -8.21 Million USD | -206.06% |
| 2013 Q3 | 437.04 Thousand USD | 8.22% |
| 2013 Q2 | 403.85 Thousand USD | 0.0% |
| 2012 FY | -2.68 Million USD | 53.59% |
| 2012 Q4 | 524.51 Thousand USD | 0.0% |
| 2012 Q3 | 524.51 Thousand USD | 0.0% |
| 2011 Q1 | -2.38 Million USD | -172.18% |
| 2011 Q3 | -7.02 Million USD | -1815.98% |
| 2011 Q4 | -2.54 Million USD | 63.78% |
| 2011 FY | -5.78 Million USD | -169.3% |
| 2011 Q2 | -366.85 Thousand USD | 84.63% |
| 2010 FY | 8.35 Million USD | 16.75% |
| 2010 Q4 | 3.3 Million USD | -24.93% |
| 2010 Q3 | 4.4 Million USD | 2867.4% |
| 2010 Q2 | 148.41 Thousand USD | -69.82% |
| 2010 Q1 | 491.67 Thousand USD | 165.28% |
| 2009 Q4 | -753.19 Thousand USD | -127.91% |
| 2009 FY | 7.15 Million USD | -63.66% |
| 2009 Q1 | -1.41 Million USD | -182.04% |
| 2009 Q2 | 6.62 Million USD | 567.03% |
| 2009 Q3 | 2.69 Million USD | -59.26% |
| 2008 Q1 | 7.32 Million USD | 122.41% |
| 2008 Q3 | 8.72 Million USD | 358.11% |
| 2008 Q4 | 1.72 Million USD | -80.19% |
| 2008 FY | 19.68 Million USD | 64.58% |
| 2008 Q2 | 1.9 Million USD | -73.98% |
| 2007 Q2 | 2.33 Million USD | -23.53% |
| 2007 FY | 11.95 Million USD | 1622.31% |
| 2007 Q3 | 1.95 Million USD | -16.42% |
| 2007 Q1 | 3.05 Million USD | 6421.31% |
| 2007 Q4 | 3.29 Million USD | 68.32% |
| 2006 Q1 | -38.98 Thousand USD | 95.62% |
| 2006 Q4 | 46.92 Thousand USD | 105.06% |
| 2006 Q3 | -927.79 Thousand USD | -790.73% |
| 2006 Q2 | 134.32 Thousand USD | 444.57% |
| 2006 FY | -785.53 Thousand USD | 41.2% |
| 2005 Q1 | -340.03 Thousand USD | -21.61% |
| 2005 Q2 | -1.09 Million USD | -221.16% |
| 2005 Q3 | 995.82 Thousand USD | 191.19% |
| 2005 Q4 | -889.02 Thousand USD | -189.28% |
| 2005 FY | -1.33 Million USD | -130.24% |
| 2004 Q2 | -261.4 Thousand USD | -774.27% |
| 2004 Q3 | -56.29 Thousand USD | 78.47% |
| 2004 Q4 | -279.6 Thousand USD | -396.69% |
| 2004 FY | -580.26 Thousand USD | 44.84% |
| 2004 Q1 | 38.76 Thousand USD | 110.47% |
| 2003 Q4 | -370.43 Thousand USD | -104.77% |
| 2003 FY | -1.05 Million USD | -513.35% |
| 2003 Q3 | -180.89 Thousand USD | 26.93% |
| 2003 Q1 | -253.03 Thousand USD | 36.96% |
| 2003 Q2 | -247.55 Thousand USD | 2.16% |
| 2002 Q1 | 48.32 Thousand USD | -35.74% |
| 2002 Q4 | -401.38 Thousand USD | -484.84% |
| 2002 Q2 | 77.25 Thousand USD | 59.89% |
| 2002 FY | -171.5 Thousand USD | -146.46% |
| 2002 Q3 | 104.3 Thousand USD | 35.0% |
| 2001 Q2 | 98.03 Thousand USD | 63.99% |
| 2001 Q1 | 59.78 Thousand USD | 140.86% |
| 2001 FY | 369.1 Thousand USD | -68.13% |
| 2001 Q4 | 75.18 Thousand USD | -44.75% |
| 2001 Q3 | 136.1 Thousand USD | 38.83% |
| 2000 FY | 1.15 Million USD | 1309.27% |
| 2000 Q2 | -61.76 Thousand USD | -164.77% |
| 2000 Q1 | 95.35 Thousand USD | 132.09% |
| 2000 Q3 | 78.73 Thousand USD | 227.49% |
| 2000 Q4 | -146.29 Thousand USD | -285.8% |
| 1999 Q1 | 300 Thousand USD | 250.0% |
| 1999 FY | -95.77 Thousand USD | -110.64% |
| 1999 Q4 | -297.15 Thousand USD | -199.05% |
| 1999 Q3 | 300 Thousand USD | 400.0% |
| 1999 Q2 | -100 Thousand USD | -133.33% |
| 1998 Q4 | -200 Thousand USD | -166.67% |
| 1998 Q2 | 100 Thousand USD | 150.0% |
| 1998 FY | 900 Thousand USD | 550.0% |
| 1998 Q3 | 300 Thousand USD | 200.0% |
| 1998 Q1 | -200 Thousand USD | 80.0% |
| 1997 Q2 | 200 Thousand USD | -33.33% |
| 1997 Q1 | 300 Thousand USD | 0.0% |
| 1997 FY | -200 Thousand USD | -133.33% |
| 1997 Q4 | -1 Million USD | -300.0% |
| 1997 Q3 | 500 Thousand USD | 150.0% |
| 1996 Q3 | 300 Thousand USD | 0.0% |
| 1996 Q2 | 300 Thousand USD | 400.0% |
| 1996 Q1 | -100 Thousand USD | -150.0% |
| 1996 FY | 600 Thousand USD | -72.73% |
| 1996 Q4 | - USD | -100.0% |
| 1995 FY | 2.2 Million USD | -24.14% |
| 1995 Q3 | 200 Thousand USD | -33.33% |
| 1995 Q2 | 300 Thousand USD | -57.14% |
| 1995 Q1 | 700 Thousand USD | 75.0% |
| 1995 Q4 | 200 Thousand USD | 0.0% |
| 1994 FY | 2.9 Million USD | -17.14% |
| 1994 Q4 | 400 Thousand USD | -20.0% |
| 1994 Q3 | 500 Thousand USD | 0.0% |
| 1994 Q2 | 500 Thousand USD | 0.0% |
| 1994 Q1 | 500 Thousand USD | -44.44% |
| 1993 Q2 | 800 Thousand USD | 366.67% |
| 1993 Q4 | 900 Thousand USD | -18.18% |
| 1993 Q1 | -300 Thousand USD | 57.14% |
| 1993 Q3 | 1.1 Million USD | 37.5% |
| 1993 FY | 3.5 Million USD | -30.0% |
| 1992 FY | 5 Million USD | 1350.0% |
| 1992 Q4 | -700 Thousand USD | -158.33% |
| 1992 Q3 | 1.2 Million USD | -45.45% |
| 1992 Q2 | 2.2 Million USD | 120.0% |
| 1992 Q1 | 1 Million USD | 233.33% |
| 1991 Q3 | 700 Thousand USD | 250.0% |
| 1991 Q4 | 300 Thousand USD | -57.14% |
| 1991 Q1 | -3.3 Million USD | -430.0% |
| 1991 Q2 | 200 Thousand USD | 106.06% |
| 1991 FY | -400 Thousand USD | -107.84% |
| 1990 FY | 5.1 Million USD | 410.0% |
| 1990 Q3 | 600 Thousand USD | -14.29% |
| 1990 Q2 | 700 Thousand USD | -30.0% |
| 1990 Q1 | 1 Million USD | 42.86% |
| 1990 Q4 | 1 Million USD | 66.67% |
| 1989 FY | 1 Million USD | -81.13% |
| 1989 Q2 | 600 Thousand USD | 0.0% |
| 1989 Q1 | 600 Thousand USD | -45.45% |
| 1989 Q3 | 400 Thousand USD | -33.33% |
| 1989 Q4 | 700 Thousand USD | 75.0% |
| Name | Operating Income | Operating Income Difference |
|---|---|---|
| Akoya Biosciences, Inc. | -57.66 Million USD | 99.693% |
| AngioDynamics, Inc. | -97.71 Million USD | 99.819% |
| AtriCure, Inc. | -26.68 Million USD | 99.336% |
| Avinger, Inc. | -16.63 Million USD | 98.936% |
| Azenta, Inc. | -73.12 Million USD | 99.758% |
| BioLife Solutions, Inc. | -70.82 Million USD | 99.75% |
| The Cooper Companies, Inc. | 533.1 Million USD | 100.033% |
| Ekso Bionics Holdings, Inc. | -15.11 Million USD | 98.828% |
| Femasys Inc. | -14.5 Million USD | 98.78% |
| GlucoTrack, Inc. | -7.1 Million USD | 97.507% |
| Harvard Bioscience, Inc. | 1.89 Million USD | 109.349% |
| Hologic, Inc. | 882.6 Million USD | 100.02% |
| ICU Medical, Inc. | 22.82 Million USD | 100.776% |
| Intuitive Surgical, Inc. | 1.76 Billion USD | 100.01% |
| KORU Medical Systems, Inc. | -10.26 Million USD | 98.276% |
| LeMaitre Vascular, Inc. | 37.08 Million USD | 100.478% |
| Innovative Eyewear, Inc. | -6.9 Million USD | 97.434% |
| Innovative Eyewear, Inc. | -6.9 Million USD | 97.434% |
| Masimo Corporation | 136.5 Million USD | 100.13% |
| Microbot Medical Inc. | -9.85 Million USD | 98.203% |
| Meihua International Medical Technologies Co., Ltd. | 14.67 Million USD | 101.207% |
| Merit Medical Systems, Inc. | 123.94 Million USD | 100.143% |
| Nephros, Inc. | -1.59 Million USD | 88.884% |
| NovoCure Limited | -232.87 Million USD | 99.924% |
| NEXGEL, Inc. | -3.47 Million USD | 94.907% |
| NEXGEL, Inc. | -3.47 Million USD | 94.907% |
| Singular Genomics Systems, Inc. | -102.8 Million USD | 99.828% |
| OraSure Technologies, Inc. | 54.07 Million USD | 100.327% |
| Pro-Dex, Inc. | 7.17 Million USD | 102.469% |
| Pulse Biosciences, Inc. | -43.57 Million USD | 99.594% |
| Predictive Oncology Inc. | -13.92 Million USD | 98.728% |
| Precision Optics Corporation, Inc. | -2.72 Million USD | 93.5% |
| QuidelOrtho Corporation | 139.1 Million USD | 100.127% |
| Repligen Corporation | 54.57 Million USD | 100.324% |
| Sanara MedTech Inc. | -4.21 Million USD | 95.799% |
| STAAR Surgical Company | 28.09 Million USD | 100.63% |
| Sharps Technology, Inc. | -10.12 Million USD | 98.251% |
| Utah Medical Products, Inc. | 16.77 Million USD | 101.055% |
| DENTSPLY SIRONA Inc. | -85 Million USD | 99.792% |
| Jin Medical International Ltd. | 2.86 Million USD | 106.176% |